ClinicalTrials.gg
CompletedNCT04667195Updated Sep 14, 2022

Clinical Characteristics of Acutely Hospitalized Adults With Acute Pyelonephritis

An observational study in Acute Pyelonephritis, sponsored by University of Southern Denmark. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-14.

Sponsored by University of Southern Denmark · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
966
Ages
18 Years and older
Sex
All
01

Study summary

Acute pyelonephritis is an acute infection. Today the diagnosis is made primarily on the basis of unspecific clinical symptoms with flank tenderness combined with as a key clue. This study will investigate which clinical and paraclinical characteristics available within 4 hours of hospital stay, that describes the patients admitted in the emergency department with acute pyelonephritis the best.

Read the detailed description

Acute pyelonephritis (APN) is a severe acute infection in the upper urinary tract, which quite frequently is seen in the emergency department (ED). In our study, we define APN as a urinary tract infection with extension above the bladder, implicated by systemic affection in a suspected urinary tract infection (ie, fever, chills, malaise and/or lethargy beyond normal, signs of sepsis). Most often, an infection of the bladder ascends to the kidneys, causing APN. Symptoms and clinical affection range from mild to severe, but it is always important to recognize and treat APN fast in order to prevent progression to sepsis, renal failure and ultimately death.

The diagnosis APN is primarily made clinically based on symptoms and supported by elevated biomarkers such as C-reactive protein (CRP) and leucocytes, and positive urinary test strips. The diagnostic process can be challenging as there is often weak and atypical symptoms.

The classic symptoms indicating APN is flank tenderness, fever and nausea/vomiting. Typical symptoms of cystitis (dysuria, pollakisuria, suprapubic pain, hematuria) are possible but often absent. Especially elderly can present with more generalized signs of infection with nothing clearly indicating localization to the urinary tract. A positive urine culture verifies the diagnosis, but it is only available after a minimum of 24 hours.

In this study, we seek to identify and quantify the patient characteristics available within 4 hours of hospital stay in patients with APN. The objectives are:

  • To identify clinical and paraclinical relevant information available within 4 hours of admission that are associated with APN patients
  • To investigate the association between adverse events and clinical and paraclinical relevant information in patients with APN.
02

Conditions studied

  • Acute Pyelonephritis

Keywords

  • symptoms
  • Acute Pyelonephritis
  • clinical characteristics
  • upper urinary tract infection
  • Emergency department
03

In context

Urinary Tract Infections

803 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

This study's enrollment of 966 is above the median of 236 across 198 observational studies indexed under Urinary Tract Infections.

Browse Urinary Tract Infections studies →

Lead sponsor

University of Southern Denmark is the lead sponsor of 336 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Acutely admitted patients with suspected APN from three emergency departments in the Region of Southern Denmark (Hospital Sønderjylland, Hospital Lillebælt, Odense University Hospital)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Suspicion of APN assessed by the receiving physician.

Exclusion criteria

Exclusion Criteria:

  • If the attending physician considers that participation will delay a life-saving treatment or patient needs direct transfer to the intensive care unit.
  • Admission within the last 14 days
  • Verified COVID-19 disease within 14 days before admission
  • Pregnant women
  • Severe immunodeficiencies: Primary immunodeficiencies and secondary immunodeficiencies ( positive CD4 \<200, Patients receiving treatment (ATC L04A), treatment (>20 mg/day prednisone or equivalent for >14 days within the last 30 days), Chemotherapy within 30 days)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
966 participants (actual)
Patient registry
No

Groups and cohorts

  • Suspected acute pyelonephritis

    Diagnosis of APN suspected at the initial clinical assessment by the receiving emergency department physician

    Other: Clinical assessment

Interventions

  • OtherClinical assessment

    Within 4 hours of admission to the emergency department, clinical assessment will include: * Demographics, * comorbidity, * symptoms, * objective findings, * triage at admission, * blood test results, * urine test results

06

What researchers measure

Primary outcomes

  1. Verified and non verified APN

    The decision of whether patients admitted with suspicion of APN actually has a final diagnosis of APN is based on a combination of all findings during admission. The verification of diagnosis requires human handling, interpretation and judgment. Therefore, in this study, an expert panel will define the reference standard for the diagnosis APN. The expert panel consists of two independent consultants from the emergency department with significant experience in emergency medicine and acute infections. They will individually determine whether or not the patient admitted suspected with APN actually had this diagnosis. The final diagnosis will be based on all available relevant information from the patient medical record including MRI of the kidneys. A standardized template will be used. Disagreement will be discussed until a consensus is reached.

    Time frame: 2 months after patient discharge

Secondary outcomes

  1. Intensive care treatment

    Transfer to the intensive care unit will be recorded during the current hospitalization as a binary variable (transferred/not-transferred)

    Time frame: within 60 days from admission to the emergency department

  2. Length of hospital stay

    days spent in hospital during current admission

    Time frame: within 60 days from current admission to the emergency department

  3. 30-days mortality

    binary

    Time frame: within 30 days from arrival day

  4. Readmission

    If a subject is admitted over a 30 day period after the current hospitalization discharge measured as a binary outcome

    Time frame: 30 days from day of discharge

  5. In-hospital mortality

    binary

    Time frame: within 60 days from current admission to the emergency department

Other outcomes

  1. 90-days mortality

    binary

    Time frame: within 90 days from day of admission

  2. Level of infection markers

    Concentration of serum procalcitonin, CRP and suPAR

    Time frame: within 4 hours from admission

  3. Urological intervention

    Binary

    Time frame: within 60 days from current admission to the emergency department

  4. Bacteriuria

    Binary outcome defined by microbiologist on urine culture analysis

    Time frame: within 4 hours from admission

07

Study locations

1 site
  • Hospital of Southern Jutland
    Aabenraa, Denmark
08

References and documents

Publications

  • Johnson JR, Russo TA. Acute Pyelonephritis in Adults. N Engl J Med. 2018 Jan 4;378(1):48-59. doi: 10.1056/nejmcp1702758. No abstract available. Erratum In: N Engl J Med. 2018 Mar 15;378(11):1069. doi: 10.1056/NEJMx180009. PubMed 29298155 ↗
  • Ramakrishnan K, Scheid DC. Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician. 2005 Mar 1;71(5):933-42. Erratum In: Am Fam Physician. 2005 Dec 1;72(11):2182. PubMed 15768623 ↗
  • Skjot-Arkil H, Heltborg A, Lorentzen MH, Cartuliares MB, Hertz MA, Graumann O, Rosenvinge FS, Petersen ERB, Ostergaard C, Laursen CB, Skovsted TA, Posth S, Chen M, Mogensen CB. Improved diagnostics of infectious diseases in emergency departments: a protocol of a multifaceted multicentre diagnostic study. BMJ Open. 2021 Sep 30;11(9):e049606. doi: 10.1136/bmjopen-2021-049606. PubMed 34593497 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Feb 2022, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2020
First posted
Dec 14, 2020
StartActual
Mar 1, 2021
Primary completionActual
Feb 28, 2022
CompletionActual
Jun 1, 2022
Last update
Sep 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04667195
Responsible party
Sponsor
First posted
Dec 14, 2020
Start date
Mar 1, 2021
Primary completion
Feb 28, 2022
Completion
Jun 1, 2022
Last update
Sep 14, 2022

Study contacts

Christian Backer Mogensen
study chair · Institute for Regional Health Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion